Lilly(Eli) & Co

NYSE:LLY   3:59:59 PM EDT
236.69
-1.17 (-0.49%)
4:30:09 PM EDT: $236.72 +0.03 (+0.01%)
Products, Regulatory

Lilly Says Mirikizumab Demonstrates Superiority Over Placebo In Phase 3 Maintenance Study In Ulcerative Colitis

Published: 12/14/2021 22:12 GMT
Lilly(Eli) & Co (LLY) - Mirikizumab Demonstrates Superiority Over Placebo in Phase 3 Maintenance Study in Ulcerative Colitis, Supporting Regulatory Submissions in 2022.
Eli Lilly - Significantly More Patients Treated With Mirikizumab Maintenance Dosing Achieved Primary Endpoint of Clinical Remission at One Year (52 Weeks).
Eli Lilly - All Key Secondary Endpoints Were Met.
Eli Lilly - Plans to Submit Bla to FDA for Mirikizumab in Uc, Followed by Submissions to Other Regulatory Agencies Around World in First Half of 2022.